Table 1 Prevalence of HPV in bladder cancer
From: Human papillomavirus and bladder cancer: literature review and meta-analysis
Author. year. country | Material | Method | HPV genotypes | Case | Control | OR (95% CI) | ||
|---|---|---|---|---|---|---|---|---|
Total | HPV+ | Total | HPV+ | |||||
K.H. Kim. 1995. Korea [25] | Tissue | PCR. dot blot | 16, 18 | 23 | 8 (34.8%) | – | – | – |
Smetana Z. 1995. Israel [26] | Tissue | ISH. IHC. PCR | 16, 6, 11, 8, 18 | 110 | 59 (53.6%) | 41 | 2 (4.9%) | – |
H. LaRue. 1995. Canada [27] | Tissue | PCR. SBH | 16, 6, 11 | 71 | 28 (39.4%) | – | – | – |
A. Lopez-Beltran. 1995. Spain [28] | Tissue | PCR P. ISH | 16 | 76 | 7 (9.2%) | – | – | – |
V. Gopalkrishna. 1995. India [29] | Tissue | PCR. ISH | 16 | 10 | 1 (10.0%) | – | – | – |
P. Tenti. 1996. Italy [30] | Tissue | PCR. SBH | 16, 18 | 79 | 26 (32.9%) | – | – | – |
A. Lopez-Beltran. 1996. Spain [31] | Tissue | PCR | 16, 6 | 76 | 7 (9.2%) | – | – | – |
M. Mvula. 1996. Japan [32] | Tissue | PCR | 16 | 36 | 1 (2.8%) | – | – | – |
M. Ludwig. 1996. Germany [33] | Tissue | PCR | 6, 16, 18 | 32 | 6 (18.8%) | – | – | – |
D.L. Wang. 1996. China [34] | Tissue | PCR | 16, 18 | 72 | 40 (55.6%) | 20 | 1(5%) | – |
W. Hui. 1996.China [35] | Tissue | PCR | – | 52 | 28 (53.9%) | – | – | – |
W. Zengjun. 1996. China [36] | Tissue | PCR | 16, 18 | 34 | 14 (41.2%) | 30 | 0 | – |
K. Cooper. 1997. South Africa [37] | Tissue | ISH. PCR | – | 25 | 0 | – | – | – |
K.W. Chan. 1997. China [38] | Tissue | SBH. PCR | 18 | 20 | 6 (30.0%) | – | – | – |
O. Aynaud. 1998. France [39] | Tissue | PCR. dot blot | – | 57 | 0 | – | – | – |
P. Gazzaniga. 1998. Italy [40] | Tissue | PCR. dot blot | 16, 18 | 35 | 11 (31.0%) | – | – | – |
Ya L.S.. 1998. China [41] | Tissue | PCR | 16, 18 | 50 | 5 (10.0%) | – | – | – |
Chaomei T.W.X.Y.L.. 1998. China [42] | Tissue | PCR | – | 20 | 8 (40.0%) | 5 | 0 | – |
C. Giudici. 1998. Italy [43] | Tissue | PCR | 6, 11, 16, 18, 31, 33 | 37 | 3 (8.1%) | – | – | – |
M. Simoneau. 1999. Canada [44] | Tissue | PCR. dot blot | 6, 11, 16 | 187 | 16 (8.5%) | – | – | – |
M.I. Tekin. 1999. Turkey [45] | Tissue | PCR | 16 | 42 | 2 (4.8%) | 10 | 0 | – |
W. Dinghai. 1999. China [46] | Tissue | PCR | – | 42 | 22 (52.4%) | 20 | 2 (10.1%) | – |
T. Chen. 2000. China [47] | Tissue | PCR | 6, 11, 16, 18 | 75 | 33 (44.0%) | – | – | – |
M. Sur. 2001. USA [48] | Tissue | ISH. PCR | – | 91 | 1 (1.5%) | – | – | – |
D. Fioriti. 2003. Italy [49] | Tissue | PCR | 6 | 32 | 1 (3.1%) | 20 | 0 | – |
H.M. Khaled. 2003. Egypt [50] | Tissue | PCR | 16, 18, 6, 11 | 99 | 48 (48.5%) | – | – | – |
M.R. Barghi. 2005. Iran [51] | Tissue | PCR | 18, 6, 33 | 59 | 21 (35.6%) | 20 | 1 (5.0%) | P = 0.008 |
S. Youshya. 2005. UK [52] | Tissue | ISH. PCR | – | 78 | 0 | 20 | 0 | – |
P.M.J. Moonen. 2007 [53] | Tissue | PCR | 16, 18, 6, 11, 31, 40, 52 | 99 | 15 (15.2%) | – | – | – |
H. Badawi. 2008. Egypt [54] | Tissue | PCR | 16, 18 | 20 | 9 (45.0%) | 20 | 2 (10.0%) | – |
G. Eslami. 2008. Iran [55] | Tissue | PCR | 16, 18, 33, 31, 52 | 147 | 51 (34.7%) | 39 | 3 (7.6%) | P < 0.008 |
K. Shigehara. 2009. Japan [56] | Tissue | PCR ISH | 16, 18, 56, 33 | 72 | 14 (19.4%) | 10 | 0 | – |
T. Cai. 2010. Italy [57] | Tissue | PCR | 6, 11, 16. 18, 45, 51, 58, 59, 66 | 78 | 41 (52.6%) | 59 | 16 (27.1%) | P = 0.032 |
K. Shigehara. 2010. Japan [58] | Tissue | PCR. ISH | 16, 18, 31, 33, 52, 56, 58 | 117 | 18 (15.4%) | 10 | 0 | – |
W.B. Selma. 2010. Tunisia [59] | Tissue | PCR | – | 125 | 0 | – | – | – |
A. Sorlozano. 2010. Spain [22] | Tissue | PCR | 18, 33, 35, 39, 51, 52, 82 | 34 | 2 (5.9%) | 51 | 3 (1.5%) | – |
D. Yavuzer. 2011. Turkey [60] | Tissue | PCR | 6, 11, 16, 18, 31 | 70 | 0 | – | – | – |
J. Xiao. 2011. China [61] | Tissue | PCR | 16, 18 | 90 | 7 (7.8%) | 30 | 2 (5%) | P < 0.05 |
T. Cai. 2011. Italy [57] | Tissue | PCR | 16, 18, 31, 45 | 78 | 27 (34.6%) | 59 | 6 (10.1%) | p = 0.0009 |
M.R. Barghi. 2012. Iran [62] | Tissue | PCR | 16, 18 | 82 | 24 (29.3%) | – | – | – |
G. I. Panagiotakis. 2013. Greece [63] | Tissue | PCR | – | 30 | 0 | 30 | 0 | – |
J. Steinestel. 2013. Germany [64] | Tissue | PCR | 16 | 60 | 4 (6.7%) | – | – | – |
N. Berrada. 2013. Morocco [65] | Tissue | PCR | 18, 31 | 43 | 22 (51.2%) | 5 | 0 | – |
S.H. Kim. 2014. Korea [66] | Tissue | DNA chips | 18, 35 | 35 | 6 (17.1%) | 12 | 1 (8.3%) | P = 0.659 |
S.C. Schmid. 2015. Germany [67] | Tissue | PCR | – | 109 | 0 | 6 | 0 | – |
R. Pichler. 2015. Austria [68] | Tissue | PCR. RLB | 6, 16, 18, 45, 33 | 186 | 4 (2.2%) | – | – | – |
U.K. Mete. 2018. India [69] | Tissue | PCR | – | 50 | 0 | 10 | 0 | – |
H. Badawi. 2018. Egypt [70] | Tissue | PCR. ISH | 6, 11, 35, 39, 52, 56 | 70 | 24 (34.3%) | 30 | 0 | – |
M.A. Llewellyn. 2018.UK [71] | Tissue | PCR | 16, 18 | 689 | 1 (0.2%) | – | – | – |
I.V. Kosova. 2018. Russia [72] | Tissue | PCR | 16, 39, 45, 52, 59 | 100 | 5 (5.0%) | – | – | – |
M. Yıldızhan. 2020. Turkey [73] | Tissue | PCR | 6, 84, 53, 66 | 113 | 4 (3.5%) | 99 | 0 | P = 0.125 |
S.O. Moghadam. 2020. Iran [74] | Tissue | PCR ISH | 6, 11, 16, 18 | 106 | 24 (22.6%) | – | – | – |
Y. Yan. 2020. China [75] | Tissue | PCR | 16, 18, 33, 39 | 146 | 42 (28.8%) | – | – | – |
J. Gordetsky. 2020. USA[76] | Tissue | ISH, P16 IHC | – | 204 | 1(0.5%) | – | – | – |
T.A. Zykova. 2020. Russia [77] | Tissue | PCR | 18, 31, 39, 56, 33, 52, 59 | 46 | 6 (13.0%) | – | – | – |
Total | 4619 | 753 (16.3%) | 656 | 39 (5.95%) | Â | |||